Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines
can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T …

Although one member of the poxvirus family, variola virus, has caused one of the most
devastating human infections worldwide, smallpox, the knowledge gained over the last 30 …

Advanced cancers remain a therapeutic challenge despite recent progress in targeted
therapy and immunotherapy. Novel approaches are needed to alter the tumor …

DepoVax™ is an innovative and strongly immunogenic vaccine platform. Survivin is highly
expressed in many tumor types and has reported prognostic value. To generate tumor …

Intracellular cytokine staining is a flow cytometric technique consisting of culturing stimulated
cytokine-producing cells in the presence of a protein secretion inhibitor, followed by fixation …

Attenuated recombinant poxvirus vectors expressing heterologous antigens from pathogens
are currently at various stages in clinical trials with the aim to establish their efficacy. This is …

Modified vaccinia virus Ankara (MVA) is a promising viral vector for vaccine development.
MVA is well studied and has been widely used for vaccination against smallpox in Germany …

The RV144 phase III clinical trial with the combination of the poxvirus vector ALVAC and the
HIV gp120 protein has taught us that a vaccine against HIV/AIDS is possible but further …

The highly attenuated poxvirus strain modified vaccinia virus Ankara (MVA) has reached
maturity as a vector delivery system and as a vaccine candidate against a broad spectrum of …

Objectives The safety, immunogenicity, impact on the latent reservoir and rebound of viral
load after therapeutic HIV-1 vaccination with recombinant modified vaccinia Ankara-based …